Pulse Biosciences Inc ( (PLSE) ) has released its Q3 earnings. Here is a breakdown of the information Pulse Biosciences Inc presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Pulse Biosciences, Inc. is a bioelectric medicine company focused on developing its proprietary nPulse™ technology for non-thermal tissue ablation, primarily targeting the healthcare sector with innovative solutions for conditions such as atrial fibrillation and benign thyroid nodules.
In its latest earnings report, Pulse Biosciences announced business updates and financial results for the third quarter of 2025, highlighting progress in clinical trials and regulatory approvals for its novel nPulse technology.
Key financial metrics revealed a total revenue of $86 thousand for the quarter, with significant investments in research and development and administrative expenses leading to a GAAP net loss of $19.4 million. The company has made strides in clinical trials, enrolling subjects in studies for both soft tissue and cardiac ablation, and has received FDA approval for its surgical cardiac ablation device study.
Despite the financial losses, Pulse Biosciences continues to advance its strategic initiatives, with management expressing confidence in the potential of its nPulse technology to disrupt existing market solutions and improve patient outcomes.
Looking ahead, Pulse Biosciences remains committed to achieving further clinical and regulatory milestones, with plans to commence additional studies and expand market adoption of its innovative technology.